Skip to content

[RESEARCH BLOG] · 2026-09-24

Telix Pharmaceuticals (TLX) – Sell Signal Amid Bear‑Market Regime and $1.65 B ITM Isotope Acquisition

By Pierre Brunelle · Founder & Research Lead

TLXSELLBEARsell flip

Telix Pharmaceuticals closed at $11.31 on 2026‑09‑24, up 0.35 % from the prior session. The LOPJLB proprietary model now flags a SELL directional bias with a ‑5 score, reflecting a bearish market regime that has persisted for two days.

Recent Corporate Activity

Fundamentals and Valuation

Telix’s valuation metrics remain stretched relative to peers in the biotechnology sector.

MetricValue
P/E (TTM)115.1
P/E (Forward)129.4
EV/EBITDA131.0
P/B7.66
Gross Margin52.16 %
Operating Margin‑0.73 %
Net Margin3.60 %
Debt/Equity118.9 %
Analyst Target$18.00

Trailing twelve‑month P/E sits at 115.1×, forward P/E expands to 129.4×. Enterprise‑value‑to‑EBITDA is 131.0×. The price‑to‑book multiple of 7.66× reflects premium pricing for Telix’s pipeline and isotope technology.

Profitability has improved modestly in the most recent fiscal year. Gross margin rose to 52.16 %, while operating margin remains slightly negative at ‑0.73 %, indicating continued heavy investment in R&D and commercial rollout. Net margin edged up to 3.60 %, driven by higher revenue and better cost control. Return on invested capital (ROIC) is 4.27 %, and return on equity (ROE) is 7.11 %, both modest figures that suggest the firm is still in a transition phase from a development‑heavy to a revenue‑generating model. The debt‑to‑equity ratio is elevated at 118.9 %, a product of the recent acquisition financing and ongoing capital expenditures.

Analyst sentiment remains cautiously optimistic. The consensus target price is $18.00, representing a 59 % upside from the current close, and the prevailing recommendation is Buy. This optimism is anchored in the expectation that the ITM acquisition will unlock scalable isotope production, while the newly approved Pixclara and the upcoming launch of Zircaix will diversify revenue streams.

Revenue and Earnings Trajectory

Telix’s top‑line growth has accelerated dramatically over the past five years. Revenue climbed from $5.21 M in 2020 to $1.21 B in 2025, representing a compound annual growth rate (CAGR) of roughly 140 %. The surge was driven primarily by the commercialization of its Precision Medicine segment, especially the PSMA imaging agents Gozellix and Illuccix, and the recent addition of Pixclara.

The most recent quarter (Q2 2026) posted $477 M in revenue, a 22 % year‑over‑year increase, and EBITDA expanded 146 % YoY to $52 M. Net profit after tax rose to $38 M, reflecting tighter expense discipline.

Earnings per share (EPS) have been volatile. After a deep loss period in 2020‑2022 (EPS ranging from ‑$0.17 to ‑$0.34), the company achieved a modest positive EPS of $0.02 in 2023, followed by $0.15 in 2024. However, 2025 saw a reversal to ‑$0.03, driven by higher acquisition‑related amortization and a temporary dip in operating cash flow. Free cash flow (FCF) turned negative in 2025 (‑$82.8 M), underscoring the cash‑intensive nature of the acquisition and ongoing R&D spend, which now accounts for 26 % of revenue.

The balance sheet reflects a market cap of $3.83 B. Cash and cash equivalents remain robust, but the elevated leverage (D/E = 118.9 %) warrants close monitoring, especially if integration costs exceed expectations or if regulatory timelines slip.

Earnings Call

Telix’s most recent earnings call (Q2 2026) reinforced the narrative of accelerating commercial execution and margin expansion. Management reported 22 % revenue growth to $477 M, with EBITDA improving 146 % year‑on‑year to $52 M and net profit after tax climbing to $38 M. The company maintained its full‑year revenue guidance of $950‑$970 M, emphasizing confidence in hitting the upper end of the range.

Key themes

Risks discussed

Representative quotations

“We are a pure‑play radiopharmaceutical firm, and our strength is based on five core pillars of activity.”

“The launch of Gozellix has been very successful. Demand was strong from day 1, and the adoption we've seen reinforces that our two‑product strategy is delivering exactly what we've intended.”

“EBITDA improved 146 % year‑on‑year to $52 million, and net profit after tax was up to $38 million, reflecting strong business performance and continued control of operating expenditure.”

Management tone remained stable (tone score +0.60), and the guidance stance was maintained, signaling confidence in the revenue trajectory despite the elevated leverage.

LOPJLB Signal Read

The LOPJLB engine currently assigns Telix a SELL directional signal within a BEAR market regime. The composite PERF score of 29.80 and FUND quality score of 17.74 place the stock in the lower‑mid range of the model’s risk‑adjusted spectrum.

Investors can explore the interactive chart above for a visual overlay of the underlying technical signals, and review the full methodology at the LOPJLB research methodology page.

Further Research & Disclaimers

This article is for informational purposes only and does not constitute investment advice. All opinions are those of LOPJLB’s research team and are subject to change without notice.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

Open TLX signal detail → · Open screener → · Methodology